• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Despite fewer healthcare deals, corporate venture capital booming

Despite fewer healthcare deals, corporate venture capital booming

May 16, 2014
CenterWatch Staff

While last year’s boom in corporate venture capital financing continues to expand in some business sectors, the healthcare space raised only $288 million in 23 deals in the first quarter of 2014—the lowest in five quarters.

A survey of first quarter venture capital (VC) investments by CB Insights showed a continuing trend of big companies with deep pockets making sizeable late-stage financing investments. Known as corporate venture capitalists, led by Google Ventures and Intel Capita, they invested a total of $3 billion in the first quarter, 30% of all VC investment, which totaled $9.92 billion in 880 deals.

Lilly Ventures, the investment arm of Eli Lilly, and SR One, GlaxoSmithKline’s corporate VC fund, led corporate venture investing in healthcare. While 36% of corporate VC investments were in internet companies, 18% were in healthcare, the second largest sector. Still, first quarter corporate investments in healthcare were nearly $100 million less than the year-ago quarter, when $380 million was invested.

Of the 23 corporate VC deals in the first quarter, the top three were:

  • Neotract received $51 million in late stage financing from Johnson & Johnson. It is developing minimally invasive devices that address unmet needs in urology. Last fall, the 10-year-old company gained FDA approval for UroLift, which lowers urinary tract symptoms due to Benign Prostatic Hyperplasia (BPH). The device works by opening the urethra directly without resecting or ablating prostate tissue. Last month Neotract said it gained positive insurance coverage for UroLift from Aetna U.S. Healthcare.
  • Thesan Pharmaceuticals raised $49 million in Series B funding from a group that included Novartis Venture Fund, SV Life Sciences, Lundbeckfond Ventures and Thesan’s original investor, Novo Ventures, a wholly-owned subsidiary of the Novo Nordisk Foundation. The Carlsbad, Calif.-based biotech company is developing treatments for skin disorders starting with atopic dermatitis, a form of eczema, and acne.
  • Axonics Modulation Technologies received $32.6 million from Paris-based Edmond de Rothschild Investment Partners, the private equity affiliate of the Edmond de Rothschild Group, NeoMed Management and Legend Capital. Axonics was spun out of the Alfred Mann Foundation, which is providing intellectual property and device experience in neuromodulation—the process in which several classes of neurotransmitters in the nervous system regulate diverse population of neurons. Neuromodulation involves the use of implantable devices that alter nervous system activity through the use of electrical stimulation. Irvine, Calif-based Axonics is developing novel implantable neuromodulation technology directed toward severalchronic conditions, including chronic pain and overactive bladder.

The report also highlighted the record number of U.S. initial public offerings during the first quarter—35 VC-backed companies, the highest since the third quarter of 2000. Of the 35 IPOs, 22 were in the healthcare sector, compared to four in the year-ago quarter. The remaining 13 VC-backed IPOs were technology companies.

“Healthcare remains a conundrum, with great IPO activity but more than a dip in venture financing compared to a year ago,” said Anand Sanwal, CEO of CB Insights. “It’s hard to put my finger on why it is happening, as there is an overall shift to technology investments. Still, IPOs are a better indicator of the healthcare space.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing